iSpecimen Files to Sell 488,290 Shares of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2026
0mins
iSpecimen files to sell 488,290 shares of common stock for holders
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISPC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISPC
About ISPC
iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
E.F. Hutton Secures $2.5 Million for iSpecimen
- Financing Size: E.F. Hutton acted as the exclusive placement agent for a $2.5 million private placement for iSpecimen Inc., further solidifying E.F. Hutton's financing capabilities in the healthcare and life sciences sectors.
- Historical Financing Review: In December 2025, E.F. Hutton also completed a separate private placement for iSpecimen, raising approximately $5.5 million, demonstrating its ongoing commitment and ability to support growth-oriented companies.
- Market Positioning: iSpecimen enhances access to high-quality human biospecimens through its innovative online marketplace, connecting scientists with healthcare specimen providers, thereby advancing medical research.
- Use of Funds: The net proceeds from this financing will be used for working capital and general corporate purposes, indicating the company's strategic intent to expand its market influence and support research needs.
See More
E.F. Hutton Secures $2.5 Million Financing for iSpecimen
- Financing Overview: E.F. Hutton & Co. successfully acted as the exclusive placement agent for a $2.5 million private placement for iSpecimen Inc., reinforcing its financing capabilities in the healthcare and life sciences sectors.
- Historical Financing Review: In December 2025, E.F. Hutton also completed a separate private placement for iSpecimen, raising approximately $5.5 million, demonstrating its ongoing commitment and ability to support growth-oriented companies.
- Market Positioning and Impact: iSpecimen's innovative online marketplace connects scientists with healthcare specimen providers, enhancing access to high-quality human biospecimens, thereby advancing medical research.
- Use of Proceeds and Strategic Goals: The net proceeds from this financing will be used for working capital and general corporate purposes, indicating iSpecimen's commitment to expanding its impact within the medical discovery ecosystem through ongoing strategic growth initiatives.
See More
iSpecimen Inc. Announces Private Placement of 488,281 Shares
- Private Placement Details: iSpecimen Inc. announced a private placement of 488,281 shares at $5.12 per share, expected to close on May 11, 2026, which will generate gross proceeds of $2.50 million, enhancing the company's liquidity for future growth.
- Use of Proceeds: The funds raised will be allocated to working capital, including $900,000 earmarked for marketing expenses, aimed at increasing brand awareness and market share, thereby boosting the company's competitiveness in the biospecimen market.
- Stock Price Movement: iSpecimen Inc. closed at $5.12 on Friday, down 3.21% from the previous trading day, but in pre-market trading, the stock rose 4.63% to $5.36, indicating a positive market reaction to the private placement and reflecting investor confidence in the company's future growth.
- Warrant Offering Option: In addition to common stock, iSpecimen is offering pre-funded warrants at $5.1199 each, which are immediately exercisable at a rate of 0.0001 per share, providing investors with flexibility and potential upside.
See More
iSpecimen Inc. Prices $2.5 Million Private Placement
- Financing Size: iSpecimen Inc. announced a private placement of 488,281 shares at $5.12 each, raising a total of $2.5 million, indicating strong market interest in the company.
- Use of Proceeds: The net proceeds from this financing will be allocated for working capital, with up to $900,000 specifically earmarked for marketing expenses, aimed at enhancing brand visibility and market share.
- Shareholder Approval Requirement: Under Nasdaq rules, the total number of shares issued in this transaction is capped at 19.99% of outstanding stock, necessitating the company to file a proxy statement within 30 days and hold a shareholder meeting within 90 days to seek approval, ensuring compliance.
- Stock Performance: iSpecimen closed at $5.12 on May 8, 2026, down 3.21% from the previous day, but rose 4.10% to $5.33 in after-hours trading, reflecting a positive market reaction to the financing news.
See More
iSpecimen Completes $2.5 Million Private Placement
- Financing Details: iSpecimen Inc. announced the issuance of 488,281 shares at $5.12 each, raising approximately $2.5 million, with proceeds allocated for working capital and up to $900,000 in marketing expenses, thereby enhancing the company's market outreach capabilities.
- Pre-Funded Warrant Option: Certain investors may opt for pre-funded warrants at $5.1199 each, which can be exercised immediately at a price of $0.0001 per share, providing a flexible financing structure that could attract more investors while mitigating shareholder dilution risks.
- Shareholder Approval Requirement: The number of shares issued in this offering is capped at 19.99% of the company's outstanding common stock, requiring shareholder approval within 90 days, which may impact future financing flexibility and shareholder structure.
- Compliance and Disclosure: iSpecimen plans to file a preliminary proxy statement with the SEC within 30 days post-closing and hold a shareholder meeting within 90 days to seek approval, ensuring transparency and compliance with regulatory requirements.
See More
iSpecimen Shares Surge 91% After Logistics Model Overhaul
- Logistics Model Overhaul: iSpecimen's new direct-to-customer shipping model reduces biospecimen shipping times from 7-14 days to just 1-2 days, significantly enhancing customer experience and lowering shipping costs, which is expected to attract more researchers to its platform.
- Efficiency Gains: The new system decreases transit times by 70-85%, improving reliability and specimen quality, which is critical for researchers dealing with rare or time-sensitive samples, thereby advancing medical research.
- Strengthened Global Network: By expanding partnerships across Europe and Eastern Europe, iSpecimen has fortified its global supplier network, ensuring broader access to biospecimens for life science researchers, thus enhancing the company's competitive position in the market.
- Stock Price Surge: Following the announcement of the logistics model overhaul, iSpecimen's stock surged 91% in pre-market trading, rebounding from $0.13 to $0.25, reflecting strong market confidence in the company's growth potential.
See More
E.F. Hutton Secures $2.5 Million for iSpecimen
- Financing Size: E.F. Hutton acted as the exclusive placement agent for a $2.5 million private placement for iSpecimen Inc., further solidifying E.F. Hutton's financing capabilities in the healthcare and life sciences sectors.
- Historical Financing Review: In December 2025, E.F. Hutton also completed a separate private placement for iSpecimen, raising approximately $5.5 million, demonstrating its ongoing commitment and ability to support growth-oriented companies.
- Market Positioning: iSpecimen enhances access to high-quality human biospecimens through its innovative online marketplace, connecting scientists with healthcare specimen providers, thereby advancing medical research.
- Use of Funds: The net proceeds from this financing will be used for working capital and general corporate purposes, indicating the company's strategic intent to expand its market influence and support research needs.
See More
E.F. Hutton Secures $2.5 Million Financing for iSpecimen
- Financing Overview: E.F. Hutton & Co. successfully acted as the exclusive placement agent for a $2.5 million private placement for iSpecimen Inc., reinforcing its financing capabilities in the healthcare and life sciences sectors.
- Historical Financing Review: In December 2025, E.F. Hutton also completed a separate private placement for iSpecimen, raising approximately $5.5 million, demonstrating its ongoing commitment and ability to support growth-oriented companies.
- Market Positioning and Impact: iSpecimen's innovative online marketplace connects scientists with healthcare specimen providers, enhancing access to high-quality human biospecimens, thereby advancing medical research.
- Use of Proceeds and Strategic Goals: The net proceeds from this financing will be used for working capital and general corporate purposes, indicating iSpecimen's commitment to expanding its impact within the medical discovery ecosystem through ongoing strategic growth initiatives.
See More
iSpecimen Inc. Announces Private Placement of 488,281 Shares
- Private Placement Details: iSpecimen Inc. announced a private placement of 488,281 shares at $5.12 per share, expected to close on May 11, 2026, which will generate gross proceeds of $2.50 million, enhancing the company's liquidity for future growth.
- Use of Proceeds: The funds raised will be allocated to working capital, including $900,000 earmarked for marketing expenses, aimed at increasing brand awareness and market share, thereby boosting the company's competitiveness in the biospecimen market.
- Stock Price Movement: iSpecimen Inc. closed at $5.12 on Friday, down 3.21% from the previous trading day, but in pre-market trading, the stock rose 4.63% to $5.36, indicating a positive market reaction to the private placement and reflecting investor confidence in the company's future growth.
- Warrant Offering Option: In addition to common stock, iSpecimen is offering pre-funded warrants at $5.1199 each, which are immediately exercisable at a rate of 0.0001 per share, providing investors with flexibility and potential upside.
See More
iSpecimen Inc. Prices $2.5 Million Private Placement
- Financing Size: iSpecimen Inc. announced a private placement of 488,281 shares at $5.12 each, raising a total of $2.5 million, indicating strong market interest in the company.
- Use of Proceeds: The net proceeds from this financing will be allocated for working capital, with up to $900,000 specifically earmarked for marketing expenses, aimed at enhancing brand visibility and market share.
- Shareholder Approval Requirement: Under Nasdaq rules, the total number of shares issued in this transaction is capped at 19.99% of outstanding stock, necessitating the company to file a proxy statement within 30 days and hold a shareholder meeting within 90 days to seek approval, ensuring compliance.
- Stock Performance: iSpecimen closed at $5.12 on May 8, 2026, down 3.21% from the previous day, but rose 4.10% to $5.33 in after-hours trading, reflecting a positive market reaction to the financing news.
See More
iSpecimen Completes $2.5 Million Private Placement
- Financing Details: iSpecimen Inc. announced the issuance of 488,281 shares at $5.12 each, raising approximately $2.5 million, with proceeds allocated for working capital and up to $900,000 in marketing expenses, thereby enhancing the company's market outreach capabilities.
- Pre-Funded Warrant Option: Certain investors may opt for pre-funded warrants at $5.1199 each, which can be exercised immediately at a price of $0.0001 per share, providing a flexible financing structure that could attract more investors while mitigating shareholder dilution risks.
- Shareholder Approval Requirement: The number of shares issued in this offering is capped at 19.99% of the company's outstanding common stock, requiring shareholder approval within 90 days, which may impact future financing flexibility and shareholder structure.
- Compliance and Disclosure: iSpecimen plans to file a preliminary proxy statement with the SEC within 30 days post-closing and hold a shareholder meeting within 90 days to seek approval, ensuring transparency and compliance with regulatory requirements.
See More
iSpecimen Shares Surge 91% After Logistics Model Overhaul
- Logistics Model Overhaul: iSpecimen's new direct-to-customer shipping model reduces biospecimen shipping times from 7-14 days to just 1-2 days, significantly enhancing customer experience and lowering shipping costs, which is expected to attract more researchers to its platform.
- Efficiency Gains: The new system decreases transit times by 70-85%, improving reliability and specimen quality, which is critical for researchers dealing with rare or time-sensitive samples, thereby advancing medical research.
- Strengthened Global Network: By expanding partnerships across Europe and Eastern Europe, iSpecimen has fortified its global supplier network, ensuring broader access to biospecimens for life science researchers, thus enhancing the company's competitive position in the market.
- Stock Price Surge: Following the announcement of the logistics model overhaul, iSpecimen's stock surged 91% in pre-market trading, rebounding from $0.13 to $0.25, reflecting strong market confidence in the company's growth potential.
See More
